Keyword: Sun Pharmaceutical
Here's your pharma manufacturing news of note.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Sun Pharmaceuticals said the FDA has cleared its manufacturing facility at Dadra that had received a warning letter from the agency earlier this year.
Sun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a of a host of issues that contributed to a 74% profit slide.
Sun's quarterly U.S. sales dropped 42%, BeiGene offers a public offering of $175 million and the FDA sent a Form 483 to Biocon.
Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer.
Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.
Lingering regulatory problems at the Sun Pharma plant Halol, India, have contributed to a $14.1 billion slide in founder Dilip Shanghvi’s net worth.
Sun's U.S. sales dropped 34% last quarter, Grail is merging with Hong Kong-based Cirina, Shanghai-based InventisBio raised $19 million in series B.
Sun Pharma has suffered a gut-wrenching drop in its sales in the U.S. as ongoing regulatory restraints for Sun Pharma’s key API plant in India, along with generic pricing pressures, did a number on the drugmaker’s final quarter.